Docetaxel And Epirubicin As First-Line Treatment For Patients With Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase Ii Trial

Background: Taxanes and anthracyclines are the two most active classes of cytotoxic agents in the treatment of patients with metastatic breast cancer. Epirubicin, a doxorubicin analog, has shown modest toxicity advantages when compared to the parent compound. In this Phase parallel to trial, we evaluated the activity and toxicity of a docetaxel/epirubicin combination. Methods: Thirty patients with previously untreated metastatic breast cancer were treated with docetaxel 60 mg/m(2) one-hour IV infusion and epirubicin 90 mg/m(2) IV bolus; both drugs were repeated at 21-day intervals. Patients were evaluated for response after 2 courses of treatment; responding and stable patients continued treatment for a total of 6 courses. Results: Fifteen patients ( 50 percent) had objective response to treatment; an additional 20 percent of patients had stable disease of more then 6 months duration. The median and 2-year progression-free survivals were 12 months and 34 percent, respectively. Median and 2- year overall survivals were 18 months and 42 percent, respectively. Myelosuppression was the most common Grade 3/4 toxicity, and 2 patients in this trial (6 percent) had treatment-related mortality associated with severe sepsis. Conclusion: The results of this Phase parallel to trial confirm previous observations regarding the efficacy and toxicity profile of the docetaxel/ epirubicin combination. This combination has activity similar to other taxane/anthracycline combinations used in the first-line treatment of metastatic breast cancer.